Cargando…
Monoclonal Antibodies Capable of Inhibiting Complement Downstream of C5 in Multiple Species
Better understanding of roles of complement in pathology has fuelled an explosion of interest in complement-targeted therapeutics. The C5-blocking monoclonal antibody (mAb) eculizumab, the first of the new wave of complement blocking drugs, was FDA approved for treatment of Paroxysmal Nocturnal Hemo...
| Autores principales: | , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Frontiers Media S.A.
2020
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7793867/ https://www.ncbi.nlm.nih.gov/pubmed/33424866 http://dx.doi.org/10.3389/fimmu.2020.612402 |